Sodium phosphate, monobasic

Sodium Phosphate, Monobasic Overview

Sodium phosphate, monobasic (also known as monosodium phosphate, NaH2​PO4​, or sodium dihydrogen phosphate) is an inorganic alkali metal phosphate salt. Chemically, it belongs to the class of alkali metal oxoanionic compounds. It exists in anhydrous, monohydrate (NaH2​PO4​⋅H2​O), and dihydrate (NaH2​PO4​⋅2H2​O) crystalline forms.

In clinical medicine, gastroenterology, and clinical nutrition, Sodium phosphate, monobasic functions as an osmotic saline laxative, electrolyte replenisher, and urinary acidifying agent (ATC codes A06AG01, A06AD17, B05XA09). When combined with sodium phosphate, dibasic, it is used as an oral bowel cleansing regimen (e.g., OsmoPrep, Visicol) or a rectal enema (e.g., Fleet Enema) for acute constipation relief and pre-colonoscopy bowel preparation. Parenterally, it serves as an IV solution additive to prevent or correct severe hypophosphatemia in patients requiring total parenteral nutrition (TPN). Orally, it is also co-formulated in urinary antiseptics (e.g., Urelle, Uribel) to acidify urine and optimize antibacterial efficacy.

What Is Sodium Phosphate, Monobasic and How Does It Work?

Sodium phosphate, monobasic is an inorganic salt that exerts its primary clinical effects through osmotic fluid shift, electrolyte replenishment, and urinary acidification.

Its primary physiological, chemical, and luminal mechanisms include:

• Osmotic Gradient Generation (Saline Laxative): Following oral or rectal administration, monobasic and dibasic phosphate ions are poorly absorbed across the intestinal mucosa. The accumulation of hypertonic phosphate solutes within the bowel lumen creates an osmotic gradient that draws water from vascular spaces into the gut.
• Luminal Distension & Peristalsis: The increased luminal water volume expands intestinal walls, inducing mechanical stretch reflexes that stimulate rapid, propulsive colonic peristalsis and evacuation within 30 minutes to 6 hours.
• Cellular Phosphate Replenishment: When infused intravenously, phosphate ions (PO43−​) restore systemic intracellular organic phosphate stores essential for adenosine triphosphate (ATP) synthesis, 2,3-diphosphoglycerate (2,3-DPG) erythrocyte function, and nucleic acid structure.
• Urinary Acidification: Renal excretion of dihydrogen phosphate ions (H2​PO4−​) increases hydrogen ion (H+) concentration in urine, lowering urinary pH to enhance the ionization and antibacterial efficacy of agents like methenamine.

Is Sodium Phosphate, Monobasic FDA Approved?

Yes, Sodium Phosphate, Monobasic is approved by the US FDA. It received its official New Drug Application approval in 2006 under the trade name OsmoPrep (manufactured by Salix Pharmaceuticals) as a fixed-dose oral tablet co-formulated with sodium phosphate, dibasic for bowel cleansing prior to colonoscopy. It is also approved in over-the-counter rectal enemas (such as Fleet Enema) and as a prescription intravenous electrolyte solution additive to treat severe hypophosphatemia.

What Is Sodium Phosphate, Monobasic Used For?

• Cleansing of the colon in adults prior to screening or diagnostic colonoscopy (oral split-dose tablets).
• Symptomatic treatment of occasional constipation (oral solutions and rectal enemas).
• Prevention and correction of hypophosphatemia in patients receiving parenteral nutrition.
• Urinary acidification to enhance urinary tract antiseptic efficacy (oral combination tablets).

Before Taking Sodium Phosphate, Monobasic: Contraindications & Precautions

Do not use if you have severe renal impairment CrCl < 30mL/min or ESRD), acute phosphate nephropathy, congestive heart failure, severe ascites, unstable angina, active hyperphosphatemia, mechanical gastrointestinal obstruction, bowel perforation, toxic megacolon, ileus, or active inflammatory bowel disease.

Who Should Not Receive Sodium Phosphate, Monobasic?

• Patients with acute phosphate nephropathy, severe renal impairment (creatinine clearance under 30 mL/min), or end-stage renal disease (ESRD).
• Patients with congestive heart failure, severe ascites, unstable angina, or active symptomatic hyperphosphatemia.
• Individuals with known or suspected mechanical gastrointestinal obstruction, bowel perforation, toxic megacolon, ileus, or active inflammatory bowel disease.
• Patients with severe electrolyte disturbances, primary hyperparathyroidism, or systemic hypernatremia.

Sodium Phosphate, Monobasic, Pregnancy & Fertility

Systemic electrolyte absorption occurs following oral or rectal saline laxative administration. Hyperphosphatemia and hypernatremia can cause maternal and fetal fluid shifts. Oral phosphate bowel prep tablets should be avoided during pregnancy unless no clinical alternatives exist. Parenteral electrolyte replacement should be monitored closely.

Tell Your Doctor Before Receiving Sodium Phosphate, Monobasic

Inform your gastroenterologist or physician if you have a history of renal dysfunction, heart failure, cardiac arrhythmias, hypocalcemia, or baseline electrolyte imbalances. Disclose all concurrent medications, particularly ACE inhibitors, ARBs, NSAIDs, or diuretics.

Sodium Phosphate, Monobasic Dosage & Administration

Formulated as oral tablets (OsmoPrep: 1.102 g monobasic / 0.398 g dibasic per tablet), rectal enemas (Fleet Enema: ~19 g monobasic / 7 g dibasic per 118 mL), or concentrated IV electrolyte additives.

Standard Sodium Phosphate, Monobasic Dosing

• Oral Colonoscopy Preparation (OsmoPrep Tablets – 1.102 g Monobasic / 0.398 g Dibasic per tablet): Total adult dosage is 32 tablets taken with clear liquids in two split doses.

• Evening Before Procedure: 4 tablets taken with 8 ounces of clear liquids every 15 minutes, for a total of 20 tablets.
• Morning of Procedure (3-5 hours prior): 4 tablets taken with 8 ounces of clear liquids every 15 minutes, for a total of 12 tablets.
• Rectal Enema (Constipation): One adult enema bottle (containing approximately 19 g monobasic / 7 g dibasic per 118 mL) administered rectally as a single dose; retain until urge to evacuate occurs (usually 2 to 5 minutes).

How Sodium Phosphate, Monobasic Is Administered

• Oral Tablets / Solutions: Administer each dose with generous amounts of clear liquids (water, clear broth, fruit juices without pulp).
• Rectal Enema: Administered with the patient lying in the left lateral position with knees bent; insert lubricated nozzle gently into the rectum.
• Intravenous Additive: Dilute thoroughly in compatible IV infusion fluids prior to administration; never inject concentrated solution directly.

Sodium Phosphate, Monobasic Clinical Efficacy & Research

Clinical trials demonstrate that oral sodium phosphate tablet regimens provide equivalent colon cleansing efficacy compared to high-volume polyethylene glycol (PEG) solutions. However, clinical safety surveillance revealed a significant risk of acute phosphate nephropathy (calcification of renal tubules leading to acute kidney injury), particularly in patients with baseline renal impairment or volume depletion. Consequently, clinical guidelines mandate careful patient screening before prescribing oral phosphate-based bowel preparations.

Sodium Phosphate, Monobasic Side Effects & Safety Profile

Common adverse reactions include abdominal bloating, nausea, abdominal cramps, vomiting, mild headache, dizziness, fatigue, and perianal discomfort. Serious adverse risks include acute phosphate nephropathy and irreversible renal failure, severe electrolyte disturbances (severe hyperphosphatemia, acute hypocalcemia with tetany or QT prolongation, hypernatremia, hypokalemia), cardiac arrhythmias, generalized seizures, and aphthous-like colonic mucosal ulcerations.

Common Sodium Phosphate Side Effects

• Gastrointestinal: Abdominal bloating, nausea, abdominal cramps, and vomiting.
• Central Nervous System: Mild headache, dizziness, and fatigue.
• Localized perianal discomfort following bowel evacuation.

Serious Sodium Phosphate Adverse Events

• Acute Phosphate Nephropathy & Renal Failure: Rapid, severe elevation in serum phosphate leading to irreversible renal tubular calcification.
• Severe Electrolyte Disturbances: Severe hyperphosphatemia, hypocalcemia (leading to tetany or QT prolongation), hypernatremia, and hypokalemia.
• Cardiac Arrhythmias & Seizures: Secondary to acute electrolyte shifts and hypocalcemia.
• Gastrointestinal Mucosal Ulcerations: Apthous-like colonic mucosal ulcerations visible during colonoscopy.

Managing Sodium Phosphate Side Effects

Ensure full compliance with mandatory hydration protocols (drinking clear fluids continuously) during bowel preparation. Monitor serum renal function and electrolytes closely if signs of severe volume depletion or muscle cramping develop.

Sodium Phosphate, Monobasic Drug Interactions & What to Avoid

Co-administration with ACE inhibitors, ARBs, or NSAIDs significantly escalates the risk of acute phosphate nephropathy and acute kidney injury. Concurrent use of diuretics (e.g., furosemide, hydrochlorothiazide) accelerates volume depletion, compounding renal toxicity and severe electrolyte shifts.

Sodium Phosphate, Monobasic Drug-Drug Interactions

• ACE Inhibitors, ARBs, & NSAIDs: Concomitant use significantly increases the risk of acute phosphate nephropathy and acute renal failure.
• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Accelerates volume depletion, compounding renal toxicity and electrolyte imbalance risks.
• Calcium Supplements & Antacids: Calcium binds phosphate in the gut, forming insoluble calcium phosphate complexes that reduce oral absorption.

Sodium Phosphate, Monobasic, Food & Alcohol

Patients undergoing bowel preparation must adhere strictly to a clear liquid diet. Avoid solid foods, milk, and liquids containing red or purple dyes. Avoid alcohol consumption, which worsens dehydration.

Sodium Phosphate, Monobasic: Missed Dose, Overdose & Storage

Completing all specified tablet doses with clear liquids is mandatory for adequate mucosal visualization; if a dose is delayed or missed, contact the endoscopist immediately. Acute overdose causes severe hyperphosphatemia, profound hypocalcemia, hypernatremia, severe tetany, seizures, cardiac arrest, and acute renal failure, requiring immediate emergency medical intervention (intravenous fluid hydration, forced diuresis, IV calcium gluconate, and hemodialysis).

Missed Dose of Sodium Phosphate, Monobasic

For colonoscopy preparation, completing all specified tablet doses with clear liquids is mandatory. Contact your endoscopist immediately if doses are missed or delayed. For electrolyte replacement, follow physician instructions.

Sodium Phosphate, Monobasic Overdose & Emergency

Acute overdose causes severe hyperphosphatemia, profound hypocalcemia, hypernatremia, severe tetany, seizures, cardiac arrest, and acute renal failure. Seek immediate emergency medical care for IV hydration, forced diuresis, IV calcium gluconate, and hemodialysis.

How to Store Sodium Phosphate, Monobasic

Store tablets and enemas at controlled room temperature between 20°C and 25°C (68°F to 77°F). Keep strictly out of reach of children.

Sodium Phosphate, Monobasic Patient Management & Monitoring

Obtain a baseline renal function panel (serum creatinine, eGFR, BUN) and baseline serum electrolytes (phosphate, calcium, sodium, potassium) prior to prescribing oral phosphate-based bowel preparations. Ensure strict compliance with fluid ingestion protocols during preparation.

Tests Before Starting Sodium Phosphate, Monobasic

• Baseline renal function panel (serum creatinine, eGFR, BUN).
• Baseline serum electrolytes (phosphate, calcium, sodium, potassium).

Monitoring During Sodium Phosphate, Monobasic Treatment

Monitor post-procedure renal function and serum electrolytes in high-risk patients or those presenting with severe fatigue, muscle spasms, or decreased urine output.

Sodium Phosphate, Monobasic Do’s and Don’ts

• Do drink all required clear liquids with each tablet dose as instructed.
• Do notify your doctor if you take blood pressure or anti-inflammatory drugs.
• Do not use oral phosphate preparations if you have kidney disease or heart failure.
• Do not exceed recommended dosage limits for enemas or oral solutions.

Frequently Asked Questions

References

• DrugBank Database – Sodium Phosphate, Monobasic Clinical Profile (DB09449)
• Official FDA Prescribing Information – OsmoPrep (Sodium Phosphate Monobasic Monohydrate and Sodium Phosphate Dibasic Anhydrous) Tablets

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.